KR101629504B1 - Composition for improving skin conditions containing a combination of cytokines - Google Patents

Abstract

The present invention relates to a skin condition improving composition containing a major cytokine combination, and more particularly to a composition for improving skin condition comprising EGF, TGF-? 1, TGF-? 3, PDGF and VEGF as an active ingredient . The composition of the present invention is excellent in skin regeneration, fine scratch and gloss improvement effect, and the cosmetic composition, quasi-drug composition or pharmaceutical composition containing the same is remarkably excellent in skin condition improvement or prevention or treatment of skin damage.

Description

[0001] The present invention relates to a composition for improving skin condition containing a combination of cytokines,

The present invention relates to a composition containing a specific cytokine combination and a cosmetic composition, a quasi-drug, and a pharmaceutical composition using the same, and more particularly, to a composition having a skin condition improving effect by containing a main cytokine combination composed of a specific ratio, Cosmetics used, quasi-drugs, pharmaceuticals, and the like.

Skin acts as a barrier to protect the body from the outside. When such a skin is damaged, the natural healing action of the living body heals the skin. The wound healing process is divided into four stages: inflammation, reperfusion, proliferation, and maturation. In the inflammation, immune cells that migrate from the blood vessels appear at the wound site, which is usually short if there is no significant infection.

The proliferating cells include fibroblasts, inflammatory cells as well as granular tissue containing extracellular matrix components such as immature collagen, fibronectin or hyaluronic acid, . These granular tissues rapidly fill the wound area and have an organized structure, which is an important factor in wound healing. Then, the surface of the scraped wound is covered with a layer of keratinocytes, a new epidermis is formed and the epithelium is reconstructed. This means that, in the wound healing process, promoting the regeneration of fibroblast or keratinocyte cells can speed up skin wound healing and minimize scarring.

Collagen is a major substrate protein produced in the fibroblasts of the skin and exists in extracellular epilepsy. It is composed of the skin's mechanical rigidity, connective tissue resistance and tissue binding force, cell adhesion support, cell division and differentiation It is known that it plays an important function such as induction of poetry. On the other hand, retinoic acid, betulinic acid, chlorella extract and the like which promote the collagen synthesis and improve the skin condition are known as active ingredients.

The growth factor refers to a polypeptide that promotes the division, growth and differentiation of various cells, and epithelial growth factor, platelet-derived growth factor, transforming growth factor-beta, or vascular endothelial growth factor are known.

Epidermal growth factor (EGF) is a growth factor secreted not only by the skin but also by the mucous membranes such as oral and gastrointestinal tracts and promoting the growth, differentiation and division of the epithelial cells. When epidermal growth factor is damaged, It is known to prevent tissue damage from internal factors such as external infections and gastric juice.

Transforming growth factor-beta (TGF-β) is a growth factor that regulates cell division and differentiation and maintains cell homeostasis. It also induces apoptosis in several cells, and acts as a factor to inhibit cleavage in epithelial cells and cancer cells. It is known that skin can suppress whitening effect by inhibiting tyrosinase.

Platelet-derived growth factor (PDGF) is a growth factor that plays an important role in mesenchymal stem cell division during development. It is known that not only the developmental process but also the adult promotes the growth, division and migration of mesenchymal stem cells, and particularly promotes the division of fibroblasts in the skin.

Vascular Endothelial Growth Factor (VEGF) is a growth factor that plays an important role in the growth of endothelial cells especially in angiogenesis.

However, the growth factors are limited in the use amount due to safety problems such as irritation and reddening when applied to the skin, or the effect is insignificant, so that there is a problem that the effect of improving the skin condition by promoting the collagen synthesis of the skin can not be expected. Therefore, there is a desperate need to develop an active ingredient that is safe to the living body, stable in its effective component, and has remarkably excellent effects of preventing or treating skin damage or improving skin condition.

The object of the present invention is to provide a composition having an excellent effect of improving the skin condition by increasing the total amount of the wound healing-related proteins.

Another object to be solved by the present invention is to provide a cosmetic composition, a quasi-drug composition or a pharmaceutical composition having an excellent skin condition-improving effect by containing the composition.

In order to solve the above problems, the present invention provides a composition for improving skin condition comprising EGF, TGF-? 1, TGF-? 3, PDGF and VEGF as an active ingredient.

The inventors of the present invention have been studying the effect of improving the skin condition of a composition comprising cytokine as an active ingredient, while a composition containing a combination of major cytokines at a specific ratio has a synergistic effect, Regeneration, skin fine scratches and improvement in glossiness are remarkably excellent, and the present invention has been completed.

The composition may comprise 0.01-1 μg of EGF, 0.1-3 μg of TGF-β1, 0.1-3 μg of TGF-β3, 0.1-5 μg of PDGF and 0.01-1 μg of VEGF per ml of the composition. Preferably, the composition may comprise 0.05-0.3 μg of EGF, 0.5-1.5 μg of TGF-β1, 0.5-1.5 μg of TGF-β3, 1.5-3 μg of PDGF and 0.2-0.8 μg of VEGF per ml of the composition. More preferably, the composition may comprise from 0.1 to 0.2 μg of EGF, from 0.8 to 1.2 μg of TGF-β1, from 0.8 to 1.2 μg of TGF-β3, from 1.8 to 2.5 μg of PDGF and from 0.3 to 0.7 μg of VEGF per ml of the composition. For the purpose of the present invention, in the case of a composition containing a specific combination of cytokines as described above, a synergistic effect superior to the maximum effect exhibited by each cytokine occurs, and the skin condition improving effect is most excellent.

The term "skin" as used in the present invention means a tissue covering the body surface of an animal, and is a concept of the broadest notion including a scalp and a hair as well as a tissue covering a body surface such as a face or a body. The term "skin condition improvement" may mean, for example, skin regeneration, skin wound healing, skin moisturization, skin elasticity improvement, skin wrinkle prevention or improvement, skin fine scratch improvement or skin gloss improvement, It is not.

The present invention provides a cosmetic composition for skin condition improvement comprising the skin condition improving composition. The content of the skin condition improving composition contained in the cosmetic composition may be 1 to 20 wt%, preferably 5 to 15 wt%, and most preferably 7 to 13 wt% based on the total weight of the cosmetic composition . When the composition for improving the skin condition is contained in an amount of less than 1% by weight, the effect of improving the skin condition is insignificant. When the composition is contained in an amount of more than 20% by weight, the stability of the cosmetic preparation is problematic, .

The cosmetic composition of the present invention can be used as a cosmetic composition in the form of a solution, an external ointment, a cream, a foam, a nutritional lotion, a flexible lotion, a pack, a flexible water, an emulsion, a makeup base, But are not limited to, formulations selected from the group consisting of pastes, gels, lotions, powders, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays.

The cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a cosmetic composition for general skin. Examples of the cosmetic composition include ordinary ingredients such as oil, water, a surfactant, a moisturizer, a lower alcohol, , A chelating agent, a coloring agent, a preservative, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.

The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the formulation of the cosmetic composition.

When the formulations of the present invention are ointments, pastes, creams or gels, the carrier component may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc, zinc oxide May be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and the like may be used as a carrier component. In particular, But are not limited to, propellants such as rocaborn, propane / butane or dimethyl ether. These may be used alone or in combination of two or more.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent may be used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil and the like can be used, and particularly fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sorbitan May be used, but is not limited thereto. These may be used alone or in combination of two or more.

When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, but are not limited thereto. These may be used alone or in combination of two or more.

The present invention provides a quasi-drug composition for skin condition improvement comprising the skin condition improving composition.

The term "quasi-drug product" used in the present invention means products that are less active than drugs, among the products used for diagnosing, treating, improving, alleviating, treating or preventing diseases of human or animal. For example, Quasi-drugs are products that are used for the purpose of treating or preventing diseases of humans or animals, products that are mild or have no direct action on the human body.

The quasi-drug composition of the present invention can be prepared by a formulation selected from the group consisting of body cleansers, foams, masks, ointments, creams, lotions, essences and sprays, but is not limited thereto.

The present invention provides a pharmaceutical composition for preventing or treating skin damage comprising the skin condition improving composition. The term "skin damage" refers to any disease that can be treated due to an increase in the total amount of collagen in the skin tissue. Non-limiting examples of such skin damage include skin micro-scratches, skin abrasions, scars caused by abrasions, and the like.

The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier in addition to containing at least one selected from the group consisting of EGF, TGF-? 1, TGF-? 3, PDGF and VEGF as an active ingredient .

In the present invention, the expression "pharmaceutically acceptable " means that it can be routinely used in the pharmaceutical field, without disturbing the biological activity and properties of the compound to be administered, without irritating the organism upon administration thereof.

In the present invention, the type of the carrier is not particularly limited and any carrier conventionally used in the art can be used. Examples of the carrier include, but are not limited to, saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, . These may be used alone or in combination of two or more.

In addition, the pharmaceutical composition of the present invention may be supplemented with other pharmaceutically acceptable additives such as excipients, diluents, antioxidants, buffers or bacteriostats, and may be used as fillers, extenders, wetting agents, disintegrants, , A binder, a lubricant, and the like may be additionally used.

The pharmaceutical composition of the present invention may be formulated into various formulations suitable for oral administration or parenteral administration.

Non-limiting examples of such oral dosage forms include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs .

In order to formulate the pharmaceutical composition of the present invention for oral administration, a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, or gelatin; Excipients such as dicalcium phosphate and the like; Disintegrating agents such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax may be used, and sweeteners, fragrances, syrups and the like may also be used. .

Furthermore, in the case of capsules, in addition to the above-mentioned substances, liquid carriers such as fatty oils can be further used.

Non-limiting examples of the parenteral preparation include injectable solutions, suppositories, respiratory inhalation powders, aerosol formulations for spray, mouth spray, mouthwash, toothpaste, ointment, powder for application, oil, have.

In order to formulate the pharmaceutical composition of the present invention for parenteral administration, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations and external preparations may be used. Examples of the non-aqueous solutions and suspensions include propylene glycol, polyethylene Glycerol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like.

More specifically, when the pharmaceutical composition of the present invention is formulated into an injection, the composition of the present invention is mixed with water or a stabilizer or buffer in water to prepare a solution or suspension, which is then mixed with an ampoule or a vial Unit dosage form. When the pharmaceutical composition of the present invention is formulated into an aerosol formulation, a propellant or the like may be added together with the additive such that the water-dispersed concentrate or the wet powder is dispersed.

When the pharmaceutical composition of the present invention is formulated into an ointment, cream, or the like, it is possible to use an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Or the like can be used as a carrier.

The pharmaceutical composition of the present invention may preferably be formulated into a parenteral dosage form, and more preferably, it may be a gel, a patch, a spray, an ointment, a warning agent, a lotion agent, a liniment agent, a pasta agent and a cataplasma agent Lt; RTI ID = 0.0 > a < / RTI >

The pharmaceutically effective amount and the effective dose of the pharmaceutical composition of the present invention may be varied depending on the formulation method, administration method, administration time and / or administration route of the pharmaceutical composition, and the reaction to be achieved by the administration of the pharmaceutical composition The type and severity of the subject to be treated, the type of subject to be treated, age, weight, general health condition, symptom or degree of disease, sex, diet, excretion, drugs used simultaneously or simultaneously with the subject, And other factors well known in the medical arts, and those skilled in the art will readily determine and prescribe dosages that are effective for the desired treatment. The pharmaceutical composition of the present invention may be administered once a day or divided into several doses. Accordingly, the dosage is not limited in any way to the scope of the present invention.

A preferable dosage of the pharmaceutical composition of the present invention may be 0.1 mg / kg to 100 mg / kg per day.

The route of administration and the mode of administration of the pharmaceutical composition of the present invention may be independent of each other, and the method is not particularly limited, and any route of administration and administration method may be used as long as the pharmaceutical composition can reach the desired site You can follow. The pharmaceutical composition may be administered orally or parenterally.

The parenteral administration may be, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration or subcutaneous administration, and a method of applying, spraying or inhalation the composition to a diseased site may also be used But are not limited to.

The pharmaceutical composition of the present invention may preferably be administered parenterally, more preferably, topically applied to a site where improvement of the skin condition or prevention or treatment of skin damage is required.

As used herein, the term "prevention " means any action that inhibits or delays skin damage, including skin wounds, fine scratches, or skin scarring, by administering the pharmaceutical composition of the present invention to a subject.

The term "treatment" as used in the present invention means any action that improves or alleviates skin damages such as skin wounds, fine scratches or skin scars by administering the pharmaceutical composition of the present invention to an individual.

The present invention provides a method for improving the skin condition comprising administering to the individual a cosmetic composition for improving skin condition or a quasi-drug composition. The term "individual" as used herein refers to all animals, including mammals including livestock, humans, and the like. Such "improvement of skin condition" may mean, for example, skin regeneration, skin wound healing, skin moisturization, skin elasticity improvement, skin wrinkle prevention or improvement, skin fine scratch improvement or skin gloss improvement, It is not.

The present invention also provides a method for preventing or treating skin damage comprising administering to a subject a pharmaceutical composition for preventing or treating skin damage.

The composition of the present invention is excellent in skin regeneration, fine scratch improvement, and gloss improvement effect, and the cosmetic composition, quasi-drug composition or pharmaceutical composition containing the same is remarkably excellent in skin condition improvement or prevention or treatment of skin damage.

FIG. 1 is a graph comparing the cytokine and the amount (%) of increase in total amount of collagen of Example 1, respectively.
Fig. 2 shows experimental results comparing the dermal wound healing effect (scratch reduction rate).
Fig. 3 is a graph comparing the dermal wound healing effect (scratch reduction rate).
Fig. 4 shows experimental results comparing the wound healing effect (scratch reduction rate) of the epidermal wound.
FIG. 5 is a graph showing a comparison of the epidermal wound healing effect (scratch reduction rate).

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

Experimental Example  1: Wound healing ( Wound healing ) Related proteins ( Protein ) Measuring total effect

(Procollagen type-1 C-peptide EIA kit, Takara, Japan) was used to measure the increase in the total amount of procollagen. Human fibroblasts were added to 24-well plates at a density of 5 x 10 ⁴ cells / ml, and the growth factors (Comparative Examples 1 to 5) and the Example 1 medium were added at a concentration of 37 캜 and 5% CO ₂ And cultured in an incubator for 48 hours. 100 μl of antibody-POD conjugate solution (antibody-POD conjugate sol) (100 μl) was added to 96-well anti-PIP antibody-coated plate, and each growth factor (Comparative Examples 1 to 5 ), 20 mu l of the medium of Example 1 and standard solution were added and shaded with aluminum foil, followed by incubation at 37 DEG C for 3 hours. After removing the culture medium, the cells were washed 4 times with PBS, 100 μl of the substrate solution was added, and the mixture was allowed to stand at room temperature for 15 minutes. Then, 100 μl of H ₂ SO ₄ was added thereto and light absorbance was measured at 450 nm. As a result of the experiment, it was confirmed that in the medium of Example 1 containing the content showing the maximum efficacy when the cytokine was combined, there was an effect of increasing the total amount of collagen more than the conventional one in a concentration dependent manner. Table 1 shows the amount (%) of increase in the total amount of collagen, which is shown in FIG. 1 as a graph.

Category (μg / ml) Total collagen growth rate (%) No additives 0 EGF 3 9.52976 15 17.35628 20 15.80184 TGF-β1 10 23.39 100 32.9 110 33.28 TGF-β3 10 15.49 100 33.23 110 30.29 PDGF 25 10.68 100 15.78 150 13.67 VEGF 25 10.62 50 13.02 60 14.01 Example 1 20 26.62367 200 52.35986 300 50.33

Preparation of wound base material (X5-WF ^TM )

Based on the results of Experimental Example 1, the content of Example 1 was determined. In the case of Example 1, the mixture of the main growth factors of the functional groups secreted during the wound healing process is a raw material adjusted to the respective ratio so as to exhibit the maximum effect. The composition of Example 1 exhibits a better effect than the maximum effect exhibited by each growth factor. Table 2 shows the production ratios of the base material of wound base of Example 1.

ingredient Example 1 (μg / ml) EGF 0.14 TGF-β1 One TGF-β3 One PDGF 2.2 VEGF 0.56

Experimental Example  2: Measure wound healing effects at the cellular level

Dermal and epidermal wound healing effects measurement

The wound healing effect was measured using a scratch assay method. HaCaT cells were plated at a density of 1 × 10 ⁵ cells / ml and HF cells at a density of 5 × 10 ⁴ cells / ml in a 24-well plate, and then 10% FBS (Gibco), 100 μg / ml streptomycin, Well for 48 hours in a 5% CO ₂ incubator at 37 占 폚 using DMEM medium supplemented with 0.25 占 퐂 / ml penicillin and amphotericin B. Experiments were performed if the cells were over 80% of the wells. The medium containing the cells was cut with a 1 ml pipet tip, scratched with a constant force, and then scratched to 90 degrees on the line to finally make a cross shape. After the culture medium was removed and washed twice with PBS, the wells were treated with no treatment, positive control (FBS 5%) and the medium of Example 1, and the scratches were photographed for the first time and the before length was measured. After 24 hours of incubation at 37 ° C, 5% CO ₂ , a scratch photo was taken and the after length was measured. As a result of the experiment, it was confirmed that both the dermis and the epidermis improved the wound healing effect in Example 1 with no addition (control group). It was also confirmed that the treatment of Example 1 at 10% by weight had better effects than the positive control. Experimental results comparing the dermal wound healing effect (scratch reduction rate) are shown in Fig. 2, and a comparative graph is shown in Fig. In addition, the results of the comparison of the epidermal wound healing effect (scratch reduction rate) are shown in FIG. 4, and a comparative graph is shown in FIG. Table 3 shows dermal wound healing effects and Table 4 shows epidermal wound healing effects.

division Dermal scratch improvement rate (%) No additives 100 Positive control 172.603 Example 1
(weight%) 10% 300.062 One% 92.2029

division Epidermal scratch improvement rate (%) No additives 100 Positive control 381.724 Example 1
(weight%) 10% 430.855 One% 312.783

Example  1 as an active ingredient Cosmetics  Composition

The prescription examples are shown in Table 5 below. As shown in Experimental Examples 1 and 2, 10% by weight of Example 1, which is excellent in efficacy and safety, was prepared as an active ingredient. According to the preparation method thereof, raw materials 3 to 4 were first added, the raw materials 5 to 7 were sufficiently dissolved after dispersing at room temperature, 8 to 10 of raw materials were added to the oil phase and sufficiently dissolved at 70 ° C. Slowly dissolving the raw material 12 and finally adding Example 1 and the fragrance. The ingredients and contents of the cosmetic composition (Example 2) containing Example 1 as an active ingredient are shown in Table 5 below.

turn Raw material name Content (% by weight) Example 2 Comparative Example 1 One Example 1 10 - 2 Purified water To 100 To 100 3 Hydroxyethyl cellulose 0.05 0.05 4 Acrylate / C10-30 alkyl acrylate crosspolymer 0.08 0.08 5 glycerin One One 6 Glycereth-26 3.5 3.5 7 Tree sodium 0.01 0.01 8 Butylene glycol 0.8 0.8 9 Dipropylene glycol 5.2 5.2 10 1,2-hexanediol 2 2 11 Cetearyl alcohol 0.15 0.15 12 Tromethamine 0.08 0.08 13 Spices 0.05 0.05

Experimental Example  3: Evaluation of skin luster effect

The cosmetic composition of Example 2 was evaluated for skin glare-improving effect as follows. Twenty-one women aged 25 to 49 were asked to use the test product twice a day for four weeks. The evaluation was made by skin gloss evaluation using Skin Gloss Meter, facial image capture using Bisia-CR at each evaluation point before use, 2 weeks after use, and 4 weeks after use. As a result of evaluating the improvement effect of skin glossiness, significant improvement effects were confirmed before use and compared with Comparative Examples. After 2 weeks and 4 weeks after use, statistically significant improvement was observed at 5.22% and 9.30%, respectively. Table 6 below shows the skin lightening improvement effect (%) in comparison.

Example 2 Comparative Example 1 Before use 61.13 After 2 weeks of use 64.32 62.1 After 4 weeks of use 66.81 63.33

Experimental Example  4: Fine skin scratch  effect

In Example 2, the skin micro-scratch improvement and prevention effects were evaluated as follows.

1-1. The skin micro-scratch improvement effect was evaluated as follows. After inducing a scratch on the left arm of 24 women in their 30s and 40s, the forearm was applied to the forearm region. The application region was designated as the test site, and the non-embedding region and the comparative application region were designated as the control region. The improvement effect was tested by time zone.

1-2. The skin micro-scratch prevention effect was evaluated as follows. The sample application area should be applied to the forearm on the right arm of 24 women in their 30s and 40s as a test site, and the non - embedding site and the comparative application site should be designated as a control site. After that, the skin scratch induction degree was checked to test the preventive effect.

Image evaluation using Visioscan and image analysis using Image pro were used for the evaluation of each test. 1-1, the skin micro-scratch improvement effect was evaluated to be 98.27%, 99.48%, 99.74%, and 99.90% immediately after use, 30 minutes, 60 minutes, 120 minutes, %, And 99.85%, respectively. The scratch area reduction rate was statistically significant compared to the uncoated areas. In the case of 1-2, the applied area is statistically significantly lower than 863%, which is an increase rate of scratch increase of 85.28%, to help prevent scratch (damage) caused by skin irritation gave. Table 7 shows the skin micro scratch improvement effect (%), and Table 8 shows skin micro scratch prevention effect.

Martial arts Example 2 Comparative Example 1 Immediately after application 5.97 98.27 90.35 30 minutes later 27.02 99.48 91.47 After 60 minutes 44.31 99.74 92.44 After 120 minutes 59.45 99.90 92.75 After 180 minutes 69.58 99.85 93.01

Martial arts Example 2 Comparative Example 1 Scratch Growth Rate (%) 863.00 85.28 680.47

Claims (8)

0.01 to 1 μg of epidermal growth factor (EGF), 0.1 to 3 μg of transforming growth factor-β1, 0.1 to 3 μg of transforming growth factor-β3, 0.1 to 3 μg of platelet-derived growth factor (PDGF) To 5 μg and VEGF (vascular endothelial growth factor) of 0.01 to 1 μg as an active ingredient. delete delete The cosmetic composition for improving skin condition according to claim 1, wherein the content of the composition is 1 to 20% by weight based on the total weight of the cosmetic composition. 0.01 to 1 μg of epidermal growth factor (EGF), 0.1 to 3 μg of transforming growth factor-β1, 0.1 to 3 μg of transforming growth factor-β3, 0.1 to 3 μg of platelet-derived growth factor (PDGF) To 5 μg and VEGF (vascular endothelial growth factor) of 0.01 to 1 μg as an active ingredient. 0.01 to 1 μg of epidermal growth factor (EGF), 0.1 to 3 μg of transforming growth factor-β1, 0.1 to 3 μg of transforming growth factor-β3, 0.1 to 3 μg of platelet-derived growth factor (PDGF) (VEGF) (vascular endothelial growth factor) in an amount of 0.01 to 1 μg as an active ingredient.
delete delete

Images